Cotización Medicenna Therapeutics - MDNA

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

1.36

Postura de Compra

1.34

Postura de Venta

1.39

Volume Operado de la Acción

86,595

1.35 Rango del Día 1.43

0.41 Rango de 52 semanas 2.98

Capitalización de Mercado [m]

94.706M

Precio Anterior

1.35

Precio de Apertura

1.35

Hora

100

1.36

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

87,699

Acciones en circulación

69,637,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-3.69

Beneficio por acción (BPA)

-0.37

turnover

Beneficio neto

-25.47M

Sector

Biological Pds,ex Diagnstics

Industria

Biological Pds,ex Diagnstics

Sitio web

www.medicenna.com

Sede

Toronto, Ontario, Can

Fundado

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.35. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.41 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $94.01 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -3.69.

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.03	-2.15827338129	1.39	1.53	1.34	47907	1.38983506	CS
4	-0.46	-25.2747252747	1.82	1.83	1.3	82444	1.47071203	CS
12	-0.95	-41.1255411255	2.31	2.62	1.27	87699	1.76005614	CS
26	-0.6	-30.612244898	1.96	2.62	1.27	74071	1.9510773	CS
52	0.905	198.901098901	0.455	2.98	0.41	102999	1.85231991	CS
156	-0.58	-29.8969072165	1.94	2.98	0.215	63720	1.4192085	CS
260	-2.14	-61.1428571429	3.5	7.25	0.215	71441	2.73948201	CS

MDNA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Medicenna Therapeutics?

El precio actual de las acciones de Medicenna Therapeutics es $ 1.36

¿Cuántas acciones de Medicenna Therapeutics están en circulación?

Medicenna Therapeutics tiene 69,637,000 acciones en circulación

¿Cuál es la capitalización de mercado de Medicenna Therapeutics?

La capitalización de mercado de Medicenna Therapeutics es CAD 94.01M

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Medicenna Therapeutics?

Medicenna Therapeutics ha negociado en un rango de $ 0.41 a $ 2.98 durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Medicenna Therapeutics?

El ratio precio/beneficio de Medicenna Therapeutics es -3.69

¿Cuál es la moneda de reporte de Medicenna Therapeutics?

Medicenna Therapeutics presenta sus resultados financieros en CAD

¿Cuál es el último beneficio anual de Medicenna Therapeutics?

El último beneficio anual de Medicenna Therapeutics es CAD -25.47M

¿Cuál es la dirección registrada de Medicenna Therapeutics?

La dirección registrada de Medicenna Therapeutics es 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2

¿Cuál es la dirección del sitio web de Medicenna Therapeutics?

La dirección del sitio web de Medicenna Therapeutics es www.medicenna.com

¿En qué sector industrial opera Medicenna Therapeutics?

Medicenna Therapeutics opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BSXBelo Sun Mining Corp	$ 0.145 (70.59%)	2.66M
BABYElse Nutrition Holdings Inc	$ 0.035 (16.67%)	1.44M
AVNTAvant Brands Inc	$ 1.15 (12.75%)	5.76k
FSYForsys Metals Corp	$ 0.65 (12.07%)	201.28k
LCFSTidewater Renewables Ltd	$ 0.76 (11.76%)	12.7k
BYLBaylin Technologies Inc	$ 0.34 (-12.82%)	167.6k
TVA.BTVA Group Inc	$ 0.92 (-12.38%)	1.4k
FRXFennec Pharmaceuticals Inc	$ 7.90 (-12.12%)	1.65k
YRBYorbeau Resources Inc	$ 0.04 (-11.11%)	751.5k
NUMINuminus Wellness Inc	$ 0.045 (-10.00%)	59.54k
RYRoyal Bank of Canada	$ 175.51 (0.80%)	7.73M
ENBEnbridge Inc	$ 64.50 (0.16%)	5.98M
CXBCalibre Mining Corp	$ 2.51 (2.87%)	4.9M
CNQCanadian Natural Resources Ltd	$ 45.46 (0.15%)	4.43M
CMCanadian Imperial Bank of Commerce	$ 91.48 (-0.07%)	4.35M